Accelerated decline in renal function after acute myocardial infarction in patients with high low-density lipoprotein-cholesterol to high-density lipoprotein-cholesterol ratio

Heart and Vessels

Volumn 29, Issue 1, 2014, Pages 7-14

  Okumura, Satoshi ^a   Sakakibara, Masaki ^b   Hayashida, Ryo ^a   Jinno, Yasushi ^b   Tanaka, Akihito ^b   Okada, Koji ^b   Hayashi, Mutsuharu ^a   Ishii, Hideki ^a   Murohara, Toyoaki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Handa City Hospital   (Japan)

Author keywords

Acute myocardial infarction; Lipids; Low density lipoprotein cholesterol to high density lipoprotein cholesterol ratio; Renal function; Statin

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ADULT; AGE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGE FACTORS; AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CREATININE; DISEASE PROGRESSION; DYSLIPIDEMIAS; FEMALE; GLOMERULAR FILTRATION RATE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PYRROLES; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84899055858     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-012-0321-y     Document Type: Article

References (41)

1. Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, Kapadia SR, Nissen SE (2007) Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297:499-508 (Pubitemid 46220805)
2. Matsumoto I, Miyake Y, Mizukawa M, Takagi Y (2011) Impact of low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio on long-term outcome in patients undergoing percutaneous coronary intervention. Circ J 75:905-910
3. Mulec H, Johnsen SA, Wiklund O, Björck S (1993) Cholesterol: a renal risk factor in diabetic nephropathy? Am J Kidney Dis 22:196-201 (Pubitemid 23203518)
4. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R (1998) Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 158:998-1004 (Pubitemid 28213577)
5. Samuelsson O, Mulec H, Knight-Gibson C, Attman PO, Kron B, Larsson R, Weiss L, Wedel H, Alaupovic P (1997) Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 12:1908-1915 (Pubitemid 27379464)
6. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ (2005) Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 58:293-301
7. Mänttäri M, Tiula E, Alikoski T, Manninen V (1995) Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 26:670-675
8. Hillege HL, van Gilst WH, van Veldhuisen DJ, Navis G, Grobbee DE, de Graeff PA, de Zeeuw D (2003) Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J 24(5):412-420 (Pubitemid 36286184)
9. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T, Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.JAMA 285:1711-1718 (Pubitemid 32259905)
10. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350:1495-1504 (Pubitemid 38477774)
11. Kanadaşi M, Çayli M, Demirtaş M, İnal T, Demor M, Koç M, Avkaroǧullari M, Dönmez Y, Usal A, Alhan CC, Şan M (2006) The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome with low-density lipoprotein cholesterol. Heart Vessels 21:291-297
12. Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, French WJ, National Registry of Myocardial Infarction 4 Investigators (2005) Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 96:611-616 (Pubitemid 41207298)
13. Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, West M, Packard C, Curhan GC (2005) Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 112:171-178 (Pubitemid 40982298)
14. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Collaborators developing the Japanese equation for estimated GFR (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982-992
15. Nakamura H, Mizuno K, MEGA Study Group (2008) Lowered ratio of low-density lipoprotein cholesterol to high-density lipoprotein cholesterol with lipid-lowering therapy associated with reduction of cardiovascular events in primary prevention: MEGA Study post hoc analysis. Circulation 118:S-1174
16. Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, Pencina MJ, Schoonmaker C, Wilson PW, D'Agostino RB, Vasan RS (2007) Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 298(7):776-785 (Pubitemid 47263160)
17. Franssen R, Monajemi H, Stoes ES, Kastelein JJ (2011) Obesity and dyslipidemia. Med Clin N Am 95(5):893-902
18. Sakamoto T, Kojima S, Ogawa H, Shimomura H, Kimura K, Ogata Y, Sakaino N, Kitagawa A, Multicenter Study for Aggressive Lipid-Lowering Strategy by HMG-CoA Reductase Inhibitors in Patients With Acute Myocardial Infarction Investigators (2006) Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol 97:1165-1171
19. Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, Demitriadis DS, Kontopoulos AG (2002) Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 18:220-228
20. Burne-Taney MJ, Liu M, Ascon D, Molls RR, Racusen L, Rabb H (2006) Transfer of lymphocytes from mice with renal ischemia can induce albuminuria in naïve mice: a possible mechanism linking early injury and progressive renal disease? Am J Physiol Renal Physiol 291:F981-F986 (Pubitemid 44772031)
21. Hörbelt M, Lee SY, Mang HE, Knipe NL, Sado Y, Kribben A, Sutton TA (2007) Acute and chronic microvascular alterations in a mouse model of ischemic acute kidney injury. Am J Physiol Renal Physiol 293:F688-F695 (Pubitemid 47403338)
22. Zager RA, Johnson AC, Becker K (2011) Acute unilateral ischemic injury induces progressive renal inflammation, lipid accumulation, histone modification, and "end-stage" kidney disease. Am J Physiol Renal Physiol 301:F1334-F1345
23. Amdur RL, Chawla LS, Amodeo S, Kimmel PL, Palant CE (2009) Outcomes following diagnosis of acute renal failure in U.S. veterans: focus on acute tubular necrosis. Kidney Int 76:1089-1097
24. Wald R, Quinn RR, Luo J, Li P, Scales DC, Mamdani MM, Ray JG, University of Toronto Acute Kidney Injury Research Group (2009) Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. JAMA 302:1179-1185
25. Lo LJ, Go AS, Chertow GM, McCulloch CE, Fan D, Ordoñez JD, Hsu CY (2009) Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int 76:893-899
26. Ishani A, Xue JL, Himmelfarb J, Eggers PW, Kimmel PL, Molitoris BA, Collins AJ (2009) Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol 20:223-228
27. Wi J, Ko YG, Kim JS, Kim BK, Choi D, Ha JW, Hong MK, Jang Y (2011) Impact of contrast-induced acute kidney injury with transient or persistent renal dysfunction on long-term outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention. Heart 97:1753-1757
28. Athyros VG, Kakafika AI, Papageorgiou AA, Pagourelias ED, Savvatianos SD, Elisaf M, Karagiannis A, Tziomalos K, Mikhailidis DP (2007) Statin-induced increase in HDL-C and renal function in coronary heart disease patients. Open Cardiovasc Med J 1:8-14
29. Fielding CJ, Fielding PE (1995) Molecular physiology of reverse cholesterol transport. J Lipid Res 36:211-228
30. Robbesyn F, Augé N, Vindis C, Cantero AV, Barbaras R, Negre-Salvayre A, Salvayre R (2005) High-density lipoproteins prevent the oxidized low-density lipoprotein-induced epidermal [corrected] growth factor receptor activation and subsequent matrix metalloproteinase-2 upregulation. Arterioscler Thromb Vasc Biol 25:1206-1212 (Pubitemid 40776610)
31. Moorhead JF, Chan MK, El-Nahas M, Varghese Z (1982) Lipid nephrotoxicity in chronic progressive glomerular and tubulointerstitial disease. Lancet 2:1309-1311 (Pubitemid 13240921)
32. Abrass CK (2004) Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 24:46-53
33. Patel PJ, Khera AV, Jafri K, Wilensky RL, Rader DJ (2011) The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. J Am Coll Cardiol 58:2068-2075
34. Lee TM, Lin MS, Tsai CH, Chang NC (2005) Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers. Kidney Int 68:779-787 (Pubitemid 43323134)
35. Buemi M, Allegra A, Corica F, Aloisi C, Giacobbe M, Pettinato G, Corsonello A, Senatore M, Frisina N (2000) Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clin Pharmacol Ther 67:427-431 (Pubitemid 30246821)
36. Zhou Q, Liao JK (2010) Pleiotropic effects of statins: basic research and clinical perspectives. Circ J 74:818-826
37. Skogastierna C, Luksha L, Kublickiene K, Eliasson E, Rane A, Ekström L (2011) Beneficial vasoactive endothelial effects of fluvastatin: focus on prostacyclin and nitric oxide. Heart Vessels 26:628-636
38. Lunder M, Ziberna L, Janić M, Jerin A, Skitek M, Sabovič M, Drevenšek G (2012) Low-dose atorvastatin, losartan, and particularly their combination, provide cardiovascular protection in isolated rat heart and aorta. Heart Vessels. doi:10.1007/s00380-012-0259-0
39. Amann K, Benz K (2011) Statins: beyond lipids in CKD. Nephrol Dial Transplant 26:407-410
40. Fried LF (2008) Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease. Kidney Int 74:571-576
41. D'Amico G (2006) Statins and renal disease: from primary prevention to renal replacement therapy. J Am Soc Nephrol 17:S148-S152